Combat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study
Combat Medical (Combat), a medical device company optimising the delivery and efficacy of cancer therapeutics, today announced new real-world data showing 68% high-grade recurrence-free survival (HG-RFS) at 12 months in…